Cite This        Tampung        Export Record
Judul Glioblastoma : State of the Art and Future Perspectives / Edited by Ghazaleh Tabatabai and Hiroaki Wakimoto
Pengarang Tabatabai, Ghazaleh
Wakimoto, Hiroaki
Penerbitan Switzerland : MDPI - Multidisciplinary Digital Publishing Institute, 2020
Deskripsi Fisik 786 p. :ilus
ISBN 978-3-03928-261-6
Subjek Carcinoid tumor
Catatan Glioblastoma is an aggressive incurable primary tumor of the central nervous system. Median overall survival is in the range of 1.5 years even in selected clinical trials populations. Many features contribute to this therapeutic challenge including high intratumoral and intertumoral heterogeneity, resistance to therapy, migration and invasion, immunosuppression. With the access of novel highthroughput technologies, significant progress has been made to understand molecular and immunological signatures underlying the pathology of glioblastoma. Clinical trial designs have shifted from investigating broad “one-for-all” treatment approaches to precision oncology designs. The collection of contributions in this book aim at providing researchers and clinicians an update on different aspects of glioblastoma, i.e. progress in basic, preclinical and clinical research.
Bentuk Karya Tidak ada kode yang sesuai
Target Pembaca Tidak ada kode yang sesuai
Lokasi Akses Online https://oer.unair.ac.id/files/original/2839857ac812873dea5ac8da13d74022.pdf

 
No Barcode No. Panggil Akses Lokasi Ketersediaan
064225192 616.994 Gli Baca Online Perpustakaan Pusat - Online Resources
Ebook
Tersedia
Tag Ind1 Ind2 Isi
001 INLIS000000000164004
005 20250807112416
007 ta
008 250807################|##########|#|##
020 # # $a 978-3-03928-261-6
035 # # $a 0010-0825000070
082 # # $a 616.994
084 # # $a 616.994 Gli
245 # # $a Glioblastoma : $b State of the Art and Future Perspectives /$c Edited by Ghazaleh Tabatabai and Hiroaki Wakimoto
260 # # $a Switzerland :$b MDPI - Multidisciplinary Digital Publishing Institute,$c 2020
300 # # $a 786 p. : $b ilus
505 # # $a Glioblastoma is an aggressive incurable primary tumor of the central nervous system. Median overall survival is in the range of 1.5 years even in selected clinical trials populations. Many features contribute to this therapeutic challenge including high intratumoral and intertumoral heterogeneity, resistance to therapy, migration and invasion, immunosuppression. With the access of novel highthroughput technologies, significant progress has been made to understand molecular and immunological signatures underlying the pathology of glioblastoma. Clinical trial designs have shifted from investigating broad “one-for-all” treatment approaches to precision oncology designs. The collection of contributions in this book aim at providing researchers and clinicians an update on different aspects of glioblastoma, i.e. progress in basic, preclinical and clinical research.
650 # # $a Carcinoid tumor
700 1 # $a Tabatabai, Ghazaleh
700 1 # $a Wakimoto, Hiroaki
856 # # $a https://oer.unair.ac.id/files/original/2839857ac812873dea5ac8da13d74022.pdf
990 # # $a 064225192
Content Unduh katalog